InflaRx to Report Second Quarter 2024 Results on August 8, 2024
JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting...
JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting...
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone...
Company anticipates CMS permanent CPT(R) and HCPCS codes in the coming daysToronto, Ontario--(Newsfile Corp. - August 1, 2024) - Therma...
Amid Children’s Eye Health and Safety Month, ZEISS Recommends New SmartLife Young Lenses Designed to Meet Changing Needs of Children...
VANCOUVER, BC / ACCESSWIRE / August 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical...
NEW YORK, July 31, 2024 /PRNewswire/ -- The global laboratory automation systems market size is estimated to grow by USD...